Head-to-head evidence
Afrezza vs THDB0206
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Afrezza
Marketed by MannKind Corporation
NCT00332488 · Phase 3 · completed
The trial randomized 528 participants across three treatment groups and used an active comparator, but it was open-label rather than blinded and its primary endpoint was the surrogate measure HbA1c. The primary comparison was not met: HbA1c decreased by 0.70% with inhaled insulin plus metformin versus 0.78% with metformin plus secretagogue (p=0.420).
THDB0206
Developed by Tonghua Dongbao Pharmaceutical
NCT05834868 · Phase 3 · completed
The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. No primary endpoint results have been posted, so whether THDB0206 met its objective is unknown.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Afrezza's landscape · THDB0206's landscape